FUJIREBIO
5.3.2024 07:01:33 CET | Business Wire | Press release
Fujirebio Europe and Self-screen B.V. today announced an expansion of their commercial collaboration with the distribution of the PreCursor-M AnoGYN methylation-specific molecular assay from Self-screen B.V. The test is intended for the detection of promoter hypermethylation of the genes ASCL1 and ZNF582 and is used to test the methylations status of anal specimens for research use only (RUO). It complements Fujirebio's HPV-associated molecular test portfolio.
“The Human Papilloma Virus (HPV) test panel of Fujirebio Europe continues to grow with effective and accurate testing solutions, and we are pleased to add this new RUO methylation-based assay to our molecular testing toolbox,” says Christiaan De Wilde, CEO at Fujirebio Europe “With its unmatched accuracy and reliability, this innovative PreCursor-M AnoGYN assay represents a significant advancement for research studies in the field of anal cancer prevention. We wanted our customers to have access to this valuable research tool as soon as possible, ultimately catalyzing advancements in elimination of HPV-related diseases.”
“We are very happy with the continued partnership with Fujirebio in the distribution of Self-screen’s HPV tests and methylation tests,” says Michelle Meijer, Chief Commercial Officer at Self-screen B.V. “The PreCursor-M AnoGYN extends our offering of HPV products into the field of anal cancer. Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions. The growing medical need for better and more supportive diagnostics tools for HPV related cancers such as anal cancer drove us to the development of the PreCursor-M AnoGYN RUO assay which is now available through Fujirebio.”
About host cell DNA methylation and anal cancer
Incidence of anal cancer is increasing worldwide. The majority of anal cancers are squamous cell carcinoma (SCC) and are, like cervical cancer, mainly caused by a persistent high-risk HPV infection and preceded by high-grade squamous intraepithelial lesion (HSIL). In analogy with cervical cancer screening, the screening and treatment of HSIL to prevent anal cancer in high-risk groups are under debate. Host cell DNA methylation is an epigenetic hallmark of HPV-induced carcinogenesis. The PreCursor-M AnoGYN assay is a robust and reliable tool to further investigate host cell DNA methylation in anal carcinogenesis and study its potential as a valuable biomarker for the detection of anal (pre-)cancer.1-4
Please contact Fujirebio for further information about the local availability of the test.
About Self-screen B.V.
Self-screen B.V. is a company highly experienced in translational HPV related research, assay development and commercialization of In Vitro Diagnostics (IVD).
Our dedication is towards the development and clinical application of molecular assays for the early detection of anogenital and head & neck (pre)cancers, to the benefit of patients and health care programs around the world.
Our main focus is on cervical (pre)cancer screening and prevention. Self-screen markets two clinically validated CE-IVD assays. The HPV-Risk-Assay and the PreCursor-M+ Methylation Test, for screening and triage respectively, to support full molecular cervical screening and to assist the clinician in management of women with high-grade CIN. Recently PreCursor-M AnoGYN RUO is added. For more information, visit www.self-screen.nl.
About Fujirebio
Fujirebio is a global leader in the field of high-quality IVD testing. We have more than 50 years’ accumulated experience in the conception, development, production, and worldwide commercialization of robust IVD products.
Fujirebio has a long-lasting tradition for developing high-quality routine and truly novel biomarkers. Our IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions covering a variety of disease states.
Our global presence includes offices in the United States, Latin America, Europe and Asia as well as a vast international distribution network. For more information, visit www.fujirebio.com.
References:
- van der Zee R.P. , et al. Host cell deoxyribonucleic acid methylation markers for the detection of high-grade anal intraepithelial neoplasia and anal cancer. Clin. Infect. Dis., 68 (7); 1110-1117, 2019
- van der Zee R.P. , et al. Cancer risk stratification of anal intraepithelial neoplasia in human immunodeficiency virus-positive men by validated methylation markers associated with progression to cancer. Clin. Infect. Dis., 72 (12); 2154-2163, 2021
- van der Zee R.P. , et al. DNA methylation markers have universal prognostic value for anal cancer risk in HIV-negative and HIV-positive individuals. Mol. Oncol., 15 (11); 3024-3036, 2021, 2021
- Rozemeijer K, et al. Analytical validation and diagnostic performance of the ASCL1/ZNF582 methylation test for detection of high-grade anal intraepithelial neoplasia and anal cancer. Tumour Virus Res. 30;17:200275, 2023
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240304661911/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Owkin to License K Pro and Multimodal Data to Servier to Advance Oncology Research11.9.2026 14:00:00 CEST | Press release
Owkin, the agentic AI company pioneering the first automated AI scientist to revolutionize drug discovery and development, today announced an agreement with Servier, an independent international pharmaceutical group governed by a foundation, to license K Pro, Owkin’s AI Scientist, together with multimodal patient data to advance the company’s oncology research. Under the agreement, Owkin will make multimodal patient data from its MOSAIC network accessible for analysis to Servier’s research teams, within K Pro. This agreement is the next chapter in Owkin and Servier’s collaboration, their previous work together being in patient subgroup identification, also in oncology. K Pro is Owkin’s AI scientist. It brings multimodal patient data and specialized biological agentic AI to drive smarter and faster decision-making to each step of the pharmaceutical value chain. K Pro utilizes specialized biological tools, leveraging a decade of knowledge gained through pharmaceutical partnerships and st
Mohammed bin Rashid Al Maktoum Global Water Award Accepts Entries Until 30 September 202611.9.2026 10:09:00 CEST | Press release
The Mohammed bin Rashid Al Maktoum Global Water Award continues to attract strong interest from innovators, researchers and institutions worldwide as it enters the final phase of its fifth cycle. Overseen by the UAE Water Aid Foundation (Suqia UAE) under the umbrella of the Mohammed bin Rashid Al Maktoum Global Initiatives and with a total prize value of USD 1 million, the award promotes the development of sustainable solutions that help tackle water scarcity and improve access to safe water, particularly in communities most affected by water shortages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260911305420/en/ HE Saeed Mohammed Al Tayer, Chairman of the Board of Trustees of Suqia UAE (Photo: AETOSWire) Applicants are encouraged to submit comprehensive information about their submissions, thereby helping the judging panel evaluate the various stages and mechanisms of their innovation, including water production, treatme
SES Launches New Content Orchestration and Hybrid Delivery Platform11.9.2026 07:30:00 CEST | Press release
SES CORE enables media customers to manage, monitor and orchestrate content delivery through a single interface, increasing visibility, flexibility and signal reliability SES today announced the launch of SES CORE, the first-of-its-kind content orchestration and hybrid delivery platform, designed to enable broadcasters and media customers to manage, monitor, and enable transmission of content seamlessly via satellite, fiber, and IP. Built on infrastructure-neutral architecture, SES CORE provides a single user interface for content delivery. By bringing multiple distribution technologies into a unified orchestration layer, the platform enables customers to select the most effective content delivery path, guaranteeing service reliability and consistent delivery of high-quality content to global partners. Through SES CORE, customers gain real-time visibility into service status by monitoring active content feeds. The platform provides network performance insights, automates operational ta
Ant International's Agentic Mobile Protocol Rolls Out Globally with Wallets and Acquirers; Initiating Collaboration on KYA Interoperability Framework with Mastercard and Visa11.9.2026 05:26:00 CEST | Press release
With payment leaders accelerating adoption, the Alipay+ ecosystem — with 50+ mobile payment partners, over 10 national QR schemes and serving over 2 billion consumer accounts — is evolving into the world's largest agentic payment network for mobile commerce.During Phase I in 2026, AMP partners up with 10 leading Alipay+ digital wallets that together serve 1.5 billion user accounts, as well as 7 leading acquiring partners including Adyen, Allinpay, Checkout.com, Fiserv, Global Payments, Nuvei, and Worldline.Ant International, Mastercard, and Visa have begun collaboration on a Know-Your-Agent (KYA) interoperability framework, designed to help card networks, digital wallet ecosystems, agent platforms and marketplaces streamline agent onboarding and identification across networks, based on shared principles while preserving each network's own verification and decisioning processes. As Ant International builds out its Agentic Mobile Protocol (AMP) with deeper interoperability and open-sourc
Peter Rauch Named President of Mountain Hardwear11.9.2026 01:00:00 CEST | Press release
Columbia Sportswear Company (Nasdaq: COLM), a leading innovator in active outdoor apparel, footwear, accessories and equipment, today announced that Peter Rauch will be the new President of the Mountain Hardwear brand. Mountain Hardwear's mission is to encourage and equip people to seek wilder paths. With over 30 years of wild wisdom, Mountain Hardwear continues to offer premium technical apparel, accessories and equipment products for climbers, mountaineers, skiers, snowboarders, and trail athletes. Troy Sicotte will transition to a new role as Global Vice President, Sales for Mountain Hardwear. Mr. Rauch transitions from his current role as General Manager of Columbia Brand North America and brings nearly 20 years of leadership experience across the Columbia family of brands, deep industry knowledge and a genuine passion for the outdoors. "Throughout his career, Peter has built strong cross-functional partnerships, developed high-performing teams, and delivered meaningful business re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom